Adam J Rose, Jaclyn M W Hughto, Michael S Dunbar, Emily K Quinn, Madeline Deutsch, Jamie Feldman, Asa Radix, Joshua D Safer, Jillian C Shipherd, Julie Thompson, Guneet K Jasuja
{"title":"Trends in Feminizing Hormone Therapy for Transgender Patients, 2006-2017.","authors":"Adam J Rose, Jaclyn M W Hughto, Michael S Dunbar, Emily K Quinn, Madeline Deutsch, Jamie Feldman, Asa Radix, Joshua D Safer, Jillian C Shipherd, Julie Thompson, Guneet K Jasuja","doi":"10.1089/trgh.2021.0041","DOIUrl":null,"url":null,"abstract":"<p><p>Combination therapy with estrogen and spironolactone may help some transgender women achieve desired results. We used two databases, OptumLabs<sup>®</sup> Data Warehouse (OLDW) and Veterans Health Administration (VHA), to examine trends in feminizing therapy. We included 3368 transgender patients from OLDW and 3527 from VHA, all of whom received estrogen, spironolactone, or both between 2006 and 2017. In OLDW, the proportion receiving combination therapy increased from 47% to 75% during this period. Similarly, in VHA, the proportion increased from 39% to 69% during this period. We conclude that the use of combination hormone therapy has become much more common over the past decade.</p>","PeriodicalId":37265,"journal":{"name":"Transgender Health","volume":"8 2","pages":"188-194"},"PeriodicalIF":2.0000,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066771/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transgender Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/trgh.2021.0041","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Social Sciences","Score":null,"Total":0}
引用次数: 0
Abstract
Combination therapy with estrogen and spironolactone may help some transgender women achieve desired results. We used two databases, OptumLabs® Data Warehouse (OLDW) and Veterans Health Administration (VHA), to examine trends in feminizing therapy. We included 3368 transgender patients from OLDW and 3527 from VHA, all of whom received estrogen, spironolactone, or both between 2006 and 2017. In OLDW, the proportion receiving combination therapy increased from 47% to 75% during this period. Similarly, in VHA, the proportion increased from 39% to 69% during this period. We conclude that the use of combination hormone therapy has become much more common over the past decade.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
